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Summary
Kidney allograft status is currently characterized using the invasive percutaneous needle core
biopsy procedure. The procedure has become safer over the years, but challenges and
complications still exist including sampling error, inter-observer variability, bleeding,
arteriovenous fistula, graft loss, and even death. Because the most common type of acute rejection
is distinguished by inflammatory cells exiting the intravascular compartment and gaining access to
the renal tubular space, we reasoned that a kidney allograft may function as an in vivo flow
cytometer and sort cells involved in rejection into urine. To test this idea, we developed
quantitative polymerase chain reaction (PCR) assays for absolute quantification of mRNA and
pre-amplification protocols to overcome the low RNA yield from urine. Here, we review our
single center urinary cell mRNA profiling studies that led to the multicenter Clinical Trials in
Organ Transplantation (CTOT-04) study and the discovery and validation of a 3-gene signature of
18S rRNA-normalized measures of CD3ε mRNA and IP-10 mRNA and 18S rRNA that is
diagnostic and predictive of acute cellular rejection in the kidney allograft. We also review our
development of a 4-gene signature of mRNAs for vimentin, NKCC2, E-cadherin, and 18S rRNA
diagnostic of interstitial fibrosis/tubular atrophy (IF/TA).
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Introduction
Each year, approximately 100,000 patients compete for the 11,000 deceased donor kidneys
available for transplantation in the US and at least 5,100 deaths occur among those on the
kidney transplant wait list (1). A significant contributor to the burgeoning wait list is the
return of patients with a failed graft to the list – 15% of patients on the wait list in 2011 were
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listed for repeat transplant. The prevention of such graft failures would improve long-term
graft survival rates as well as mitigate the existing organ shortage crisis.
The causes of kidney allograft failure are multiple, with acute rejection (AR) being a major
contributor to graft loss. The incidence of AR in the United States is reported to be 11.6%
for deceased donor and 10.0% for live donor recipients (1). The incidence is higher in
studies that include surveillance biopsies. The incidence was 15.2% in the first year of
transplantation in the recent Mayo study of 797 kidney graft recipients that included
surveillance biopsies (2).
The most common type of AR is T-cell-mediated acute cellular rejection (ACR) (2–5). For
example, among the 121 AR biopsies in the Mayo study, 76 were classified as ACR, 42 as
borderline, and only 3 as antibody-mediated rejection (AMR) (2). Moreover, borderline
changes, clinical ACR, or subclinical ACR in the first year of transplantation, detected in
either a for-cause biopsy or a surveillance biopsy were all associated with a significant
increase in the incidence of interstitial fibrosis and inflammation in kidney allografts,
transplant glomerulopathy, and development of class II donor specific antibodies, and
reduced graft survival [HR=3.07, 95% confidence interval (CI), 1.92–4.94, P<0.0001]. In a
landmark study of 93,934 kidney transplantations performed in the United States between
1988 and 1996, Hariharan et al. (6) found that clinical acute rejection in the first year of
transplantation negatively impacted long-term survival of kidney allografts; whereas the
projected half-life for deceased donor grafts in those without clinical acute rejection
increased from 8.8 years for transplants performed in 1988 to 17.9 years for transplants
performed in 1995, the projected half-life increased from 7.0 years in 1988 to only 8.8 years
in 1995 for those with an episode of clinical acute rejection. In a recent analysis of 48,179
patients transplanted between 2000 and 2007 in US, an episode of AR in the first year of
transplantation was associated with an adjusted relative risk for all-cause graft loss as high
as 5.5 (7).
ACR is a risk factor for chronic rejection, manifested as interstitial fibrosis and tubular
atrophy (IF/TA) with or without concurrent inflammation in the allograft, and with
progressive loss of graft function. It has also been documented that interstitial inflammation
and tubulitis, the histological hallmarks of ACR, detected in the surveillance biopsies
performed in patients with stable graft function (8) or observed in for-cause biopsies in
patients with chronic graft dysfunction, are harbingers of graft loss (9). Importantly,
treatment of intragraft inflammation, identified by surveillance biopsies, is associated with
better graft histology and function (10, 11).
The invasive biopsy procedure to diagnose AR or IF/TA
AR and IF/TA are both diagnosed with the use of a percutaneous needle core biopsy
procedure. While the procedure has become safer over the years, challenges and
complications still exist including sampling error, inter-observer variability, bleeding,
arteriovenous fistula, graft loss, and even death (12–14). The financial costs of the procedure
are substantial, reported to be approximately $3,000 (15). With an estimated incidence of 0.4
biopsies/patient during the first year of transplantation, about 7,000 biopsies at a cost of $21
million are estimated to have been performed during the first year of transplantation in the
17,671 patients who received a kidney graft in 2011 (16, 17).
Development of urinary cell mRNA profiling as a noninvasive diagnostic tool
ACR is distinguished by interstitial inflammation and tubulitis with graft infiltrating cells
gaining entry into the tubular space. We therefore reasoned that the allograft may function as
an ‘in vivo flow cytometer’ that sorts cells involved in rejection into the urine (Fig. 1). We
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formulated the hypothesis that mRNA profiling of urinary cells would offer a noninvasive
means of diagnosing ACR and initiated urinary cell mRNA profiling studies to investigate
this concept. Because of the inherent difficulties in isolating RNA from urinary cells, we
developed a pre-amplification step that enables measurement of multiple mRNA species
from very small quantities of total RNA (18). We also developed an efficient method for
absolute quantification of transcript numbers in the PCR assays (19). Armed with these
innovations, we conducted single center studies followed by multicenter clinical trials.
Herein, we summarize our single center studies of urinary cell mRNA profiling that
provided the scientific underpinning for the multicenter CTOT-04 study and the primary
data from the CTOT-04 study. We also review our successful development of a urinary cell
based gene signature for the noninvasive diagnosis of IF/TA, the most common feature of a
failing kidney allograft.
Single Center Studies that Provided the Scientific Background for the
CTOT-04 Study
In our first urinary cell mRNA profiling study, we examined whether levels of mRNA
encoding cytotoxic attack molecules – perforin and granzyme B – are informative of human
kidney allograft status. In the granule exocytosis pathway of cell-mediated cytotoxicity, a
pathway implicated in acute cellular rejection, perforin, a pore forming protein, and
granzyme B, an inducer of apoptosis, collaborate and contribute to targeted cell death. With
the use of novel competitors, we found that the levels of mRNA for perforin in urinary cells
predicted ACR with a sensitivity of 83% and a specificity of 83%, while granzyme B
mRNA levels predicted ACR with a sensitivity of 79% and a specificity of 64% when the
data analysis was restricted to patients with a biopsy-confirmed diagnosis of ACR (20).
Serine proteinase inhibitor-9 (PI-9) is an endogenous antagonist of granzyme B. We
investigated whether urinary cell levels of PI-9 are diagnostic of kidney allograft status. In a
fashion similar to perforin and granzyme B, levels of PI-9 were associated with kidney
biopsy diagnosis and urinary cell levels of PI-9 predicted ACR with a sensitivity of 76% and
a specificity of 79% (21).
It is well documented that intraepithelial homing of T cells is contingent upon the cell
surface protein CD103. Since ACR is exemplified by tubulitis with intraepithelial homing of
alloreactive T cells, we reasoned that urinary cell levels of CD103 would be diagnostic of
ACR in the kidney allograft. This research hypothesis was validated by our finding that
urinary cell levels of CD103 are diagnostic of ACR with a sensitivity of 59% and a
specificity of 75% (22).
Chemokines and their receptors play a primary role in the trafficking of cells to
inflammatory sites. We hypothesized that urinary cell levels of IP-10 and its receptor
CXCR3 would help capture intragraft inflammation. Our research hypothesis was also based
on elegant pre-clinical experimental studies implicating IP-10 and CXCR3 in inflammatory
diseases including allograft rejection (23, 24). Our findings that AR is predicted with a
sensitivity of 100% and a specificity of 78% using urinary cell levels of IP-10 mRNA and
with a sensitivity of 63% and a specificity of 83% using urinary cell levels of CXCR3
mRNA validated our research hypothesis (25).
Multicenter CTOT-04 Study
The CTOT-04 study was a prospective observational multicenter study with an initial target
enrollment of 450 kidney transplant recipients from 5 clinical sites (3). The enrollment
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target was increased to 495 in view of dropouts and a total of 497 patients with end stage
renal disease (ESRD) were enrolled. Five patients enrolled in CTOT-04 did not receive a
kidney graft, and 7 of the 492 transplanted patients did not provide any urine specimens.
Thus, our urinary cell mRNA profiling study had 485 patients. These 485 patients provided
4300 urine specimens for urinary cell mRNA profiling and 220 of 485 patients underwent at
least one renal allograft biopsy (Fig. 2). We designed CTOT-04 as an observational study
with each of the 5 participating sites being able to use site-specific immunosuppression and
infection protocols. The rationale for this study design included the consideration that the
urine mRNA profiling results should be generalizable to the kidney transplant population
and not be restricted by the immunosuppressive regimen used in any one clinic.
Urine samples (approximately 50 ml) were collected sequentially with the pre-specified
schedule for collection being post-transplant days 3, 7, 15, and 30 and months 2, 3, 4, 5, 6, 9,
and 12, and at the time of any renal allograft biopsy, prior to treatment and 2 weeks after
biopsy (Fig. 2). All five centers followed an identical protocol with respect to urine sample
collection. Urine cell pellets were prepared at the clinical sites with the use of a standard
protocol for urine cell sedimentation, stored at −80°C and shipped in batches to the Gene
Expression Monitoring (GEM) Core at Weill Cornell Medical College, New York, NY
(WCMC).
The CTOT-04 study investigated the following hypotheses: (i) urinary cell mRNA profile at
the time of a diagnostic biopsy predicts biopsy-based diagnosis of rejection and (ii) urinary
cell mRNA profile is predictive of acute allograft rejection in the near future. We pre-
specified seven mRNAs – perforin, granzyme B, proteinase inhibitor-9 (PI-9), CD103, CD3
epsilon chain (CD3ε), interferon inducible protein-10 (IP-10), and CXCR3 – for
measurement and these members of the mRNA panel were selected on the basis of our
single center studies associating their urinary cell levels with kidney allograft status (18, 20–
22, 25). Two additional transcripts were also measured: mRNA encoding transforming
growth factor-β1 (TGF-β1) and 18S ribosomal RNA (18S rRNA). These transcripts were
included as quality control parameters (vide infra).
CTOT-04 study: methodology
We isolated total RNA from urinary cell pellets as described (3). The quantity and purity of
the RNA were measured using the NanoDrop® ND-1000 UV-Vis spectrophotometer. We
qualified a urine sample as quality control passed if in that urine sample, the 18S rRNA copy
number was greater than or equal to 5×107 and its TGF-β1 mRNA copy number was greater
than or equal to 100 copies per one microgram of RNA. With these parameters, 3559 (83%)
of the 4300 urine samples were classified as quality control passed. The median quantity of
total RNA isolated from the 3559 samples that passed quality control parameters was 560 ng
(interquartile range: 333 ng to 974 ng) and the median purity of total RNA isolated for these
samples was 1.80 (interquartile range: 1.67 to 1.89, perfect ratio: 2.0). We reverse
transcribed the total RNA to cDNA using the TaqMan reverse transcription kit on the same
day the total RNA was isolated and the total RNA was adjusted to one microgram in 100
microliters prior to reverse transcription. This adjustment normalized for the cell abundance
in individual urinary cell pellets.
We designed gene specific oligonucleotide primers and TaqMan fluorogenic probes for the
measurement of levels of mRNAs pre-specified in the CTOT-04 Protocol: CD3ε, perforin,
granzyme B, IP-10, CXCR3, CD103, TGF-β1, PI-9, and 18S rRNA. The sequence and
location of the gene specific oligonucleotide primer pairs and TaqMan probes used in the
CTOT-04 study are provided in Table 1.
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Our laboratory has developed a pre-amplification enhanced real time quantitative PCR assay
for absolute quantification of mRNA copy number (18). The PCR assay involves two steps.
In the first pre-amplification step, the mRNAs to be measured are pre-amplified using
sequence specific primer pairs without the TaqMan probe. The primary purpose of the pre-
amplification step is to facilitate measurement of multiple mRNAs from a very small aliquot
of cDNA. For example, whereas 5 microliters of cDNA is needed in the standard PCR assay
to measure a single mRNA (duplicate wells with 2.5 microliters per well), the pre-
amplification step and subsequent dilution of cDNA allows almost 50 different mRNA
species to be measured from the same 5 microliters of cDNA. In the second absolute
quantification step, the mRNA of interest is quantified with the use of a customized
amplicon to construct a reference/standard curve. In the CTOT-04 study, we used an ABI
Prism 7500/7900HT Fast detection system for the absolute quantification of mRNAs and
18S rRNA.
Statistical analysis
Details of statistical analysis including normalization, fitting the model, bootstrap model
selection, internal validation of the fitted model, and calculation of the longitudinal
perspective and retrospective trajectories have been reported (3). The validation statistics
and plots were computed using Harrell’s R package “RMS, version 2.12.2” (http://cran.r-
project.org/web/packages/rms/rms.pdf). All other analyses were performed using SAS,
version 9.3 (Cary, NC).
CTOT-04 study: results
Urinary cell levels of mRNAs are diagnostic of ACR
We investigated the hypothesis that urinary cell levels of mRNA are diagnostic of Banff
ACR. We tested this by measuring the 8 pre-specified mRNAs in 43 urine samples matched
to 43 ACR biopsies from 34 patients and comparing the levels to those found in 163 samples
matched to 163 biopsies without rejection (No Rejection Biopsy group, 126 patients) and
1540 samples from the Stable (no Biopsy) group (201 patients with urine specimens). Our
primary goal was to examine whether the urine sample would serve as a surrogate for the
invasive biopsy procedure. Thus, we used matched urine samples in those who underwent a
biopsy. In those who did not undergo a biopsy (Stable group), all QC-passed samples were
analyzed.
In accord with the research hypothesis, 18S-normalized levels of mRNA for CD3ε, perforin,
granzyme B, and IP-10 in urinary cells differed significantly among the ACR, No Rejection
Biopsy, and Stable (no biopsy) groups (P<0.0001 for all 4 mRNAs by Kruskal-Wallis test
for 3-group comparison) (Fig. 3). Pairwise group comparisons (Mann-Whitney test) showed
that the levels of mRNA for CD3ε, perforin, granzyme B, and IP-10 in the ACR group were
higher than the levels in the No Rejection Biopsy group (P<0.0001 for all 4 mRNAs) and the
Stable (no biopsy) group (P<0.0001 for all 4 mRNAs).
Table 2A shows that urinary cell levels of 18S rRNA are higher in the ACR biopsy group
than the levels in the No Rejection Biopsy group or the Stable (no biopsy) group
(P=0.0002), and are higher in the ACR group than the Borderline biopsy group (P=0.04).
Table 2A also shows that 18s rRNA normalized levels of mRNA for CXCR3 (P=0.06),
CD103 (P=0.13), and PI-9 (P=0.38) are not associated with ACR in contrast to our single
center studies showing that these mRNAs are associated with ACR (21, 22, 25). The reason
for these mRNAs not being associated with ACR in the CTOT-04 study may include: (i)
inclusion in the single center studies of patients without biopsy confirmation of allograft
status whereas every patient used to develop the diagnostic signature in CTOT-04 had
undergone an allograft biopsy, and especially (ii) analysis of levels of mRNA for association
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with ACR without 18S rRNA normalization in the single center studies versus analysis of
levels of mRNA for association with ACR after 18S rRNA normalization in the CTOT-04
study. The second point is critical since non-normalized urinary cell levels of mRNA for
CD103 (P<0.0001), CXCR3 (P<0.0001) and PI-9 (P=0.002) were all significantly associated
with ACR in the CTOT-04 study (Table 2B), consistent with our previous publications (21,
22, 25).
Development of a 3-gene diagnostic signature
A 3-gene model of 18S-normalized CD3ε mRNA, 18S-normalized IP-10 mRNA, and 18S
rRNA (all logged) was the best-fitting parsimonious model, yielding the following
diagnostic signature:
−6.1487 + 0.8534 log10(CD3ε/18S) + 0.6376 log10(IP-10/18S) + 1.6464 log10(18S)
ROC curve analysis showed that this 3-gene signature yields an AUC (area under the curve)
of 0.85 (95%CI 0.78 to 0.91, P<0.0001). Using the cutpoint of −1.213, which maximizes
Youden’s index (26), this diagnostic signature had 79% sensitivity and 78% specificity to
distinguish ACR biopsies from No Rejection biopsies (Fig. 4A). The Hosmer-Lemeshow
test (27) indicated an excellent fit of this model to the data (χ2 = 4.84, df=8, p=0.77). The 3-
gene signature also discriminated the ACR biopsy group from the Stable (no biopsy) group
(Fig. 4B). The signature marginally distinguished the No Rejection biopsy group from the
Stable (no biopsy) group (Fig. 4C).
Bootstrapped model selection and internal validation
In an initial set of 500 bootstrap samples, 18S-normalized CD3ε, 18S-normalized IP-10, and
18S (all log10 transformed) remained in the final backwards elimination models more often
than any of the other 6 mRNA measures. Bootstrap validation of this 3-gene model yielded
an optimism-corrected estimate of the AUC of 0.83, an estimate of the expected value of the
AUC in independent samples (not used to derive the diagnostic signature). The Cox’s
intercept and slope statistics were −0.06 and 0.92, respectively, and the close
correspondence of the unadjusted and optimism-adjusted calibration curves to the reference
line demonstrates lack of overfitting and generalizability of the prediction model (Fig. 4D).
Rationale for not including perforin or granzyme B in the diagnostic signature
The further inclusion of granzyme B and/or perforin was unable to significantly improve the
diagnostic signature based on IP-10, CD3ε, and 18s, due largely to their high correlations
with CD3ε. This should not detract from the fact that when considered alone, 18S-
normalized levels of granzyme B and perforin are strongly associated with ACR in
CTOT-04, confirming the results reported in earlier publications (3, 18). Also, and as
provided in the legend to Figure 4, the AUC for the combination of 18S-normalized perforin
mRNA, 18S-normalized IP-10 mRNA and 18S rRNA was 0.84 (95% CI: 0.78 to 0.90;
P<0.0001), only slightly lower than that of our best diagnostic signature, and this
combination discriminated ACR biopsies with a sensitivity of 77% and a specificity of 76%.
Importantly, this signature correlated very highly (r=0.93) with the optimal 3-gene
diagnostic signature (18S-normalized CD3ε mRNA, 18S-normalized IP-10 mRNA and 18S
rRNA, all logged).
Our findings that the signature is specific for ACR and distinguishes those with ACR from
patients with other types of rejection such as borderline rejection and acute AMR are of
considerable significance for the signature being clinically directive (3). The further
observation that the diagnostic signature score is marginally higher in Banff ACR grade I
compared to grades II or III is consistent with Banff grade I ACR being primarily interstitial
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cell infiltration and tubulitis wherein relatively more cells would be expected to have access
to urine compared to grade II/III ACRs which are characterized by mild to moderate intimal
arteritis (grade II) or by transmural arteritis and/or arterial fibrinoid change and necrosis of
medial smooth cells with accompanying lymphocytic vascular inflammation (grade III)
wherein the brunt of the injury is borne by the arterial vessel wall.
Prospective trajectory of the diagnostic signature as a function of time
since transplant
Fig. 5 illustrates the LOESS-smoothed average within-person trajectories and 95%
confidence bands of the diagnostic signature for the ACR group (Fig. 5A), No Rejection
Biopsy group (Fig. 5B), and the Stable (no biopsy) group (Fig. 5C). It is evident that a
progressive increase in the diagnostic signature is seen in the urine samples of those who
went on to develop ACR whereas the trajectories in the No Rejection Biopsy group and in
the Stable (no biopsy) group were flat and remained below the −1.213 threshold diagnostic
for ACR throughout the first 400 days post-transplant. Thus, even after excluding the urine
samples that were matched to the ACR biopsies and used to develop the diagnostic
signature, we found a clear signal by about 80 days post-transplant that the future ACR
patients have elevated values, and after about 160 days of transplantation the average value
for the future ACR patients is greater than or equal to the threshold diagnostic for ACR (Fig.
5D).
Retrospective trajectory of the diagnostic signature as a function of time prior to biopsy
Fig. 6 displays the LOESS-smoothed average within-person trajectories and 95% confidence
bands of the diagnostic signature, looking backwards from the time of biopsy (time=0), for
the ACR biopsy group (Fig. 6A) and the No Rejection Biopsy group (Fig. 6B). A
comparison of the trajectories showed a significant difference in the trajectories between the
two groups, with a marked increase in the score of the diagnostic signature during the 20-
day period leading up to the first ACR biopsy whereas the signature remained relatively flat
and well below the diagnostic threshold during the 270 days preceding a biopsy in the No
Rejection Biopsy group (Fig. 6C and Fig. 6D) (P<0.0001).
Specificity of the diagnostic signature
The ‘No Rejection biopsy group’ included biopsies that displayed histological features such
as acute tubular necrosis (n=67), tubular atrophy (n=61), interstitial fibrosis (n=52),
glomerulosclerosis (n=23), vascular narrowing (n=17), calcineurin toxicity (n=12), and/or
recurrent disease (n=2) and not infrequently more than one type of allograft pathology was
observed in a single biopsy. Also, 107 of the 163 biopsies were performed for suspected
rejection/graft dysfunction (for-cause biopsies) and the remaining 56 biopsies were
surveillance (protocol) biopsies. We investigated the performance of the 3-gene diagnostic
signature after inclusion in the non-ACR group of ALL matched and QC-passed urine
samples from the kidney graft recipients with biopsies showing borderline changes (19
samples from 17 patients), acute antibody mediated rejection (10 samples from 9 patients),
chronic allograft nephropathy (CAN)(2 samples from 2 patients), or BKV nephropathy
(BKVN)(6 samples from 5 patients).
A comparison of the levels of mRNA in the 43 matched urine specimens from 34 kidney
graft recipients with biopsy confirmed Banff ACR grade 1A or higher with all available
non-ACR biopsy matched, QC-passed urine samples from 143 patients (n= 200 samples)
showed that the signature is diagnostic of ACR with 77% specificity (95% CI: 71 to 83%)
and 79% sensitivity (95% CI: 67 to 91%) (AUC=0.83, 95% CI: 0.77 to 0.89, P<0.0001) and
thus that the performance of the signature is very similar to the original analysis that was
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restricted to ACR versus No Rejection biopsy group (that is without inclusion of the 37
urine samples from those with borderline changes, AMR, CAN or BKVN). We further
analyzed the performance of the 3-gene diagnostic signature comparing levels of mRNA in
the 43 matched urine specimens from 34 kidney graft recipients with biopsy confirmed
Banff ACR grade 1A or higher with levels of mRNA in just the 31 matched and QC-passed
urine samples from the kidney graft recipients with biopsies showing Borderline changes
(19 samples from 17 patients), AMR (10 samples from 9 patients), or CAN (2 samples from
2 patients). Despite the sample size for the comparison group being very much smaller than
in the previous analyses, this analysis showed that the signature is diagnostic of ACR with
71% specificity (95% CI: 55 to 87%) and 79% sensitivity (95% CI: 67 to 91%) (AUC=0.78,
95% CI: 0.68 to 0.89, P<0.0001) and that its performance was not significantly different
from that observed when comparing the ACR biopsy group with the No Rejection biopsy
group.
The diagnostic signature in for-cause versus surveillance biopsies
The 3-gene signature was diagnostic of ACR with 80% specificity (95% CI: 73 to 88%) and
79% sensitivity (95% CI: 66 to 92%) (AUC=0.85, 95% CI: 0.79 to 0.92, P<0.0001) when
the data were analyzed using only the 38 for-cause ACR biopsies and the 107 for-cause No
Rejection biopsies. The performance characteristics of the diagnostic signature were nearly
identical to the original analysis using both for-cause biopsies and surveillance biopsies [43
ACR biopsies vs. 163 No Rejection biopsies, 78% specificity (95% CI: 71 to 84%) and 79%
sensitivity (95% CI: 67 to 91%) (AUC=0.85, 95% CI: 0.78 to 0.91, P<0.0001)]. The 3-gene
signature was also strongly associated with the biopsy diagnosis when the analysis was
restricted to surveillance No Rejection biopsies; analysis of 43 ACRs vs. 56 surveillance No
Rejection biopsies showed that ACR was predicted with 73% specificity (95% CI: 62 to
85%) and 79% sensitivity (95% CI: 67 to 91%) and the AUC was 0.83 (95% CI: 0.75 to
0.91, P<0.0001).
The diagnostic signature in clinical versus subclinical ACR
Among the 43 ACR biopsies from the CTOT-04 patients, 38 biopsies were for-cause
biopsies, and the remaining 5 were surveillance biopsies. Among the 163 No Rejection
biopsies, 107 were for-cause biopsies, and 56 were surveillance biopsies. The mean levels of
the 3-gene diagnostic signature did not differ significantly between the 38 for-cause ACR
biopsies and the 5 surveillance ACR biopsies (P=0.78). The same is true for comparison of
the 107 for-cause and the 56 surveillance No Rejection biopsies (P=0.66). Sensitivity of
diagnostic signature was 79% in 38 for-cause biopsies and 80% in surveillance biopsies (No
difference, P=1.00). Specificity of the diagnostic signature was 80% in the 107 for-cause
biopsies and 73% in the surveillance biopsies (P=0.32).
Early or late ACR and the diagnostic signature
To examine whether the diagnostic signature tends to be higher (or lower) at the time of an
early ACR compared to a late ACR, we arbitrarily classified the 43 ACRs with matching
urine samples based on whether the ACR occurred during the first 180 days post-
transplantation (early) or thereafter (late). Nineteen ACRs qualified as early ACRs, and the
remaining 24 ACRs as late ACRs. The mean diagnostic signature score at the time of biopsy
was −0.43 (95% CI: −1.04 to +0.18) for the early ACRs and −0.37 (95% CI: −0.88 to +0.14)
for the late ACRs (P=0.87 by two tailed, unpaired t test). We also evaluated the correlation
between the diagnostic signature at the time of ACR and time since transplant (treated
continuously) and the analysis showed no relationship (r=0.00, P=0.97). Thus the level of
the diagnostic signature at the time of an ACR did not vary by time since transplant.
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Anti-rejection therapy and the diagnostic signature
We examined whether the 3-gene signature not only functions as a diagnostic signature but
also as a response-predictive biomarker. Among 43 ACR biopsies with paired urine
samples, 32 also had QC-passed urine samples 14±7 days after the incident ACR biopsy. A
comparison of the diagnostic signature values showed a significant decrease from −0.37 at
the time of ACR biopsy to −0.86 at 14±7 days post-biopsy (P=0.05). We further compared
the decrease in the value for the diagnostic signature according to whether the patient was a
‘responder’, defined as the follow-up estimated glomerular filtration rate (eGFR) being no
higher than it was at the time of the ACR biopsy or a non-responder to the initial anti-
rejection therapy. eGFR data were available at the time of biopsy and at the follow-up time
for 25 of the 32 samples and among these 25, 21 were responders and the remaining 4 were
non-responders based on the above criterion. In the 21 responders, the value for the
diagnostic signature decreased significantly from the baseline value of −0.43 to −1.08 at
14±7 days post biopsy (P=0.05); in the small number of non-responders, the decrease in the
value from +0.12 to −0.80 was even greater than in the responders (0.92 vs. 0.65), but was
not statistically significant (P=0.20). Of note, the non-responders had higher levels of the
diagnostic signature at the time of biopsy and two weeks later and among the 21 responders,
7 did not show a decrease in the value of the diagnostic signature.
CTOT-04 study: clinical implications
We have developed and validated a 3-gene molecular signature that is diagnostic of ACR.
The additional information regarding the exquisite specificity of the signature for diagnosing
ACR and serving as a robust parameter of the immune status of the kidney allograft
recipient supports the clinical utility of this new molecular signature developed and
validated in the CTOT-04 study. The clinical utility of the signature is further supported by
its ability to foretell the development of an episode of ACR (thereby facilitating preemptive
therapy). We suggest that the results from our study will be transformative in helping to
reduce the need for allograft biopsies, reducing post-transplant costs and morbidity, and
improving the care of kidney graft recipients. Moreover, the renal transplant community is
now better positioned to undertake an interventional trial of personalized
immunosuppression based on urinary cell mRNA profiles.
Noninvasive diagnosis of interstitial fibrosis and tubular atrophy (IF/TA)
To develop urinary cell mRNA profiles diagnostic of IF/TA, we collected and profiled urine
samples from kidney graft recipients whose biopsies were classified as IF/TA and from
patients whose biopsies were classified as normal biopsies (28). We collected 114 urine
samples at the time of an allograft biopsy and among the 114 allograft biopsies, 48 biopsies
from 48 patients were classified as IF/TA, and 66 biopsies from 66 patients were classified
as normal biopsies. The biopsies classified as IF/TA were clinically indicated biopsies and
the normal biopsies were surveillance biopsies. The biopsy-matched urine samples were
centrifuged and RNA was extracted from the urine cell pellet and reverse-transcribed to
cDNA, as described above. We designed oligonucleotide primers and TaqMan probes and
measured absolute levels of potentially informative mRNAs in the urine of kidney allograft
recipients with the use of pre-amplification enhanced kinetic quantitative PCR assays
developed in our laboratory. The sequence and location of the primers and TaqMan probes
used in this study are provided in Table 3.
We used a two-step approach: in the first step, we developed/discovered a urinary cell
signature diagnostic of IF/TA; in the second step, we validated the discovered signature
(Fig. 7). To accomplish discovery and validation of the signature, the 18S rRNA copy
number of the 114 patients were ranked and partitioned into consecutive triplets. Within
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each triplet, the first and third patients were assigned to the discovery set, and the second
patient was assigned to the validation set, resulting in the two sets being exactly matched on
IF/TA status and very closely matched on 18S. Twice as many patients were assigned to the
discovery set to enhance statistical power for the exploratory analyses that included a
procedure to protect against the risk of a Type I error.
Urinary cell mRNA levels are diagnostic of IF/TA
Fig. 7 is a flow chart for the discovery and validation of urinary cell mRNA profiles. Fig. 8
illustrates the predicted probability of IF/TA as a function of urinary cell mRNA copy
number in the discovery set comprised of 32 kidney graft recipients with biopsy-confirmed
IF/TA and 44 recipients with normal allograft biopsy results. According to piece-wise linear
logistic models, the levels of 12 of the 22 mRNAs were significantly associated with the
diagnosis of IF/TA after using Holm’s modified Bonferroni procedure (29) to control the
risk of a Type I error: vimentin (P<0.0001), HGF (P<0.0001), α-SMA (P<0.0001),
fibronectin 1 (P<0.0001), perforin (P=0.0002), PAI1 (P=0.0002), TGF-β1 (P=0.0004),
TIMP1 (P=0.0009), granzyme B (P=0.0009), FSP1 (P=0.006), CD103 (P=0.02), and
collagen 1A1 (P=0.04). Analysis of ROC curves showed that IF/TA is predicted quite
accurately with the use of urinary cell levels of mRNA for vimentin (AUC and 95% CI =
0.90, 0.82 to 0.97), HGF (0.91, 0.84 to 0.98), α-SMA (0.88, 0.80 to 0.95), fibronectin 1
(0.83, 0.73 to 0.93), perforin (0.83, 0.74 to 0.93), TGF-β1 (0.82, 0.72 to 0.92), TIMP1 (0.81,
0.71 to 0.90), granzyme B (0.82, 0.71to 0.92), FSP1 (0.81, 0.71 to 0.91), PAI1 (0.79, 0.68 to
0.90), collagen 1A1 (0.77, 0.66 to 0.88) or CD103 (0.76, 0.65 to 0.87).
A 4-gene model diagnostic of IF/TA in the discovery set
Vimentin and HGF had the highest AUCs, and we built a multigene prediction model of
fibrosis around vimentin in view of the potential contribution of vimentin to the
pathogenesis of fibrosis. Very interestingly, after controlling for vimentin mRNA level and
the quadratic relationship of 18S rRNA level, we found that none of the previously
significant predictors (HGF, TGF-β1, fibronectin 1, PAI1, FSP1, collagen 1A1, α-SMA,
CD103, granzyme B, or perforin) remained significantly predictive, and two of the
previously non-significant predictors, mRNA for NKCC2 and E-cadherin, became
significant (Fig. 9B,C). The composite score based on the 4-gene model (Fig. 9D) was
highly associated with the diagnosis of IF/TA (Fig. 10A). The ROC curve (Fig. 10B) shows,
for various levels of this composite score, the fraction of true positive results (sensitivity)
and false positive results (1-specificity) for distinguishing patients with IF/TA from patients
with normal biopsy results. The AUC was 0.95 (95%CI: 0.90 to 0.99, P<0.0001) and with
the use of the optimal cutpoint of 4.5, the composite score predicted IF/TA with a specificity
of 84.1% (95%CI: 73.3 to 94.9%) and a sensitivity of 93.8% (95%CI: 85.4 to 99.9%) (Fig.
10B).
Independent validation
The final diagnostic equation predicting IF/TA in the discovery set was then validated in an
independent Validation set of 38 kidney graft recipients, 16 with biopsy-proven fibrosis and
22 with normal allograft biopsy results. Fig. 10C shows the ROC curve of this equation for
the diagnosis of IF/TA. This 4-gene signature was accurately diagnostic of IF/TA; the AUC
for the diagnosis of fibrosis in the independent Validation set was 0.89 (95%CI: 0.78 to
0.99, P<0.0001) (Fig. 10C). At the composite score cutpoint of 4.5 (the same cutpoint used
in the discovery set), IF/TA was diagnosed in the validation set with a specificity of 77.3%
(95%CI: 59.8 to 94.8%) and a sensitivity of 87.5% (95%CI: 71.3 to 99.9%).
We examined the fit of the prediction model by dividing the discovery and validation sets
into sextiles of the composite score. Fig. 10D shows the predicted and observed number of
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kidney graft recipients with IF/TA, separately for each set, for each sextile. Based on the
Hosmer-Lemeshow test, the fit between the observed and the predicted number of subjects
with IF/TA in each of the sextiles was excellent (P=0.69) in the discovery set (left half of
Fig. 10D). For the Validation set (right half of Fig. 10D), the P-value was 0.04, suggesting a
good fit, given that this set was not involved in the estimation of the model.
IF/TA grades and urinary cell mRNA levels
Based on the extent of kidney cortical area affected by fibrosis, IF/TA is graded as grade I
(<25% of cortical area), grade II (26–50%), or grade III (>50%) in the Banff schema. We
investigated whether the 4-gene composite score discriminates patients with differing grades
of IF/TA from patients without IF/TA. This analysis showed that the mean composite score
of the 4-gene signature was significantly different among these four groups (P<0.0001, one-
way ANOVA) (Fig. 11). Pairwise comparisons revealed that the mean composite score of
normal biopsies were significantly different from that of grade I fibrosis (P=0.0002), grade
II fibrosis (P<0.0001), and grade III fibrosis (P<0.0001). The mean composite score,
however, did not differ significantly among the three grades of fibrosis (P=0.58). A key
finding from our study is that the differential expression of urinary cell mRNA levels was
evident even in patients with grade I IF/TA. This finding suggests that urinary cell mRNA
monitoring may be of value in detecting IF/TA before the advent of irreversible renal injury
and graft dysfunction.
Features contributory to successful noninvasive diagnosis of IF/TA
A number of features of our research design may have facilitated our development of a
simple yet robust noninvasive classifier of fibrosis using the quantification of only 4 genes
in urine samples from kidney transplant recipients. First, we measured absolute levels of
mRNA copy number, avoiding some of the ambiguities inherent to the delta-delta Ct method
of quantification of mRNA copy numbers. Second, we used a discovery set to develop a
prediction equation and identify the composite score cutpoint, and then used the same
equation and cutpoint to validate the diagnostic accuracy of the urinary cell mRNA signature
in an independent cohort of kidney allograft recipients. Third, we gave consideration to the
potential for non-linear relationships of gene expression measures to renal allograft
diagnosis, and our approach for the discovery phase of the analysis used LOESS methods to
examine the relationship of the mRNA measures to diagnosis (IF/TA vs. Normal). Another
major contributor to our successful development and validation of a diagnostic biomarker of
IF/TA is our pristine control group – urine samples from patients with normal biopsy
findings in their surveillance biopsies. Had we used urine samples from kidney allograft
recipients with acute rejection, calcineurin toxicity, or BK virus nephropathy (BKVN) as the
control group, the development of a robust biomarker that distinguishes biopsies with
fibrosis from biopsies without fibrosis may have been compromised since each of these
conditions may be associated with some degree of fibrosis.
Our urinary cell mRNA panel was also designed with due consideration that multiple cell
types and an inflammatory milieu contribute to the development of fibrosis and that fibrosis
is characterized by the accumulation of extracellular matrix proteins.
Noninvasive characterization of clinical tolerance
An important and yet unmet objective is to identify patients in whom immunosuppressive
therapy can be minimized or completely withdrawn. In a landmark study of tolerance
induction in humans, we found that intragraft levels of FoxP3 were significantly higher in
the tolerant recipients compared to recipients on standard immunosuppressive therapy (30).
We also found, in the largest study to date of kidney graft recipients who were not on any
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maintenance immunosuppressive therapy for a number of reasons, that urinary cell levels of
CD20 mRNA distinguished the tolerant group from healthy volunteers and from stable
patients on maintenance immunosuppressive therapy; urinary cell levels of FoxP3 mRNA
were also higher in the tolerant group compared to healthy volunteers (31) (Fig. 12).
Concluding remarks
Our urinary cell mRNA profiling studies have shown considerable robustness in diagnosing
AR and IF/TA in the kidney allograft and provide mechanistic insights regarding allograft
rejection and the balance between graft-destructive vs. protective forces (Fig. 13). To be
clinically useful, a diagnostic test must also be reliably reproducible from center to center
and the multi-center CTOT-04 trial not only validated the sensitivity and specificity of
urinary cell mRNA profiling for the detection of ACR but also provided the support that this
technique was feasible and collection could be performed in several transplant centers. Of
note, the CTOT-04 trial utilized a single core laboratory for the processing of all urine
samples for urinary cell mRNA profiling (3). A recent multicenter study by Keslar et al. (32)
evaluated the reproducibility of a urinary cell mRNA protocol from center to center. In this
study, six centers were sent samples, reagents, and a standardized protocol for urine gene
monitor profiling. Overall, gene expression measurements had a correlation greater than
0.938 for the samples. Measurement of a known control sample among the 6 centers was
able to be quantified within a factor of 1.5 (32).
The Keslar et al. (32) study validated the reliability of a standardized protocol for urinary
cell mRNA profiling. However, it is also worth noting that urinary cell mRNA profiling
strategies have also been evaluated in several single center studies besides Weill Cornell
Medical College. Galante et al. (33) evaluated urine specimens from 60 kidney transplant
recipients and found that levels of granzyme B, perforins, and Fas ligand were significantly
higher in the acute rejecting transplant recipients than in non-rejecting transplant recipients
and reported a sensitivity that ranged from 85% to 88% and a specificity that ranged from
55% to 100% for the 3 mRNAs measured. A study by van Ham et al. investigated 70 kidney
transplant recipients and reported that granzyme B and perforin were significantly higher in
the acute rejection than in the acute tubular necrosis or stable control patients and reported
the utility of granzyme A in the diagnosis of subclinical acute rejection (34). Both of these
studies utilized a different method of RNA extraction from the CTOT-04 study: a
guanidinium thiocyanate-phenol-chloroform based extraction in the Galante et al. (33) study
and a GenElute Mammalian Total RNA kit based extraction in the van Ham et al. (34)
study.
The benefits of urinary cell mRNA profiling include its ability to generate prognostic
information. A study by Ponciano et al. identified CD20 staining in renal biopsies with acute
rejection as being correlated with higher serum creatinine at 2 years (35). Urinary CD20
mRNA had a high sensitivity of 83% for intragraft CD20 infiltration on renal biopsy and
thus may serve as a surrogate marker for intragraft CD20 cells (35). Our single center has
reported on the utility of VP1 mRNA to detect BK virus nephropathy (36). In a follow-up
study, we reported that plasminogen activator inhibitor-1 (PAI-1) was an independent
predictor of graft loss at the time of BK virus nephropathy diagnosis (37). Such prognostic
urine biomarkers may serve as a useful tool to individualize and personalize treatment.
Future directions
While the field of urinary cell mRNA profiling has made significant strides, there are still
many potential avenues to be explored. Can urinary cell mRNA profiling replace the use of
renal biopsy in many instances where a for-cause biopsy is currently performed? Can we
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utilize a standardized urinary gene mRNA profiling protocol as a monitoring tool to prevent
the development of overt acute rejection? Can we develop a urinary mRNA gene signature
that will predict the response to anti-rejection treatment? These are just some of the future
steps necessary for personalizing care with urinary cell mRNA profiling.
Diagnosis and prognostication of native kidney diseases represents another potential use for
urinary gene expression profiling. Several studies, primarily outside the United States, have
utilized this approach to evaluate lupus nephritis. Chan et al. (38) investigated 106 lupus
patients and reported that the urinary cell levels of TGF-β1 mRNA and mRNA encoding
monocyte chemoattractant protein 1 (MCP-1) significantly correlate with overall lupus
disease activity, as measured by the SLE Disease Activity Index, and also correlate with the
histological activity index score in the lupus patients that had a kidney biopsy. A follow up
study revealed that urinary MCP-1 mRNA and FoxP3 mRNA increased and IL-17 mRNA
and GATA-3 mRNA decreased preceding development of a lupus flare (39).
Based on the data generated to date, we believe that urinary cell mRNA profiles have the
potential to accurately reflect in-vivo immune status of the kidney graft recipient and
facilitate the move from a ‘one-size fits all’ immunosuppressive regimen to transplantation
precision medicine. Recent technical advances such as deep sequencing should help identify
additional candidates informative of diagnosis and prognosis and our laboratory is beginning
to characterize the mRNA transcriptome as well as the microRNA transcriptome at an
unprecedented level of precision and incorporate the new knowledge in our urinary cell
profiling protocols.
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Fig. 1. Conceptualization of the kidney allograft as an in-vivo flow cytometer
Interstitial inflammation and tubilitis are the histological hallmarks of ACR in the kidney
allograft (left panel). Since ACR involves infiltration of T lymphocytes and additional cells
into the tubular space, the kidney allograft is conceptualized to function as an in vivo flow
cytometer (middle panel) facilitating the entry of graft destructive/protective T lymphocytes
and other immune cells and graft parenchymal cells into the urinary space. In this
formulation, urinary cell mRNA profiling reflects intragraft events deterministic of allograft
status.
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Fig. 2. Patients, biopsy results, and urine samples
A total of 4300 urine samples were collected from 485 kidney allograft patients for urinary-
cell messenger RNA (mRNA) profiling on days 3, 7, 15, and 30, in months 2, 3, 4, 5, 6, 9,
and 12 after transplantation, and at the time of any kidney-allograft biopsy and 2 weeks
thereafter. Of the 4300 urine specimens, 3559 were classified as passing quality control
(QC) and 741 were classified as not passing. A total of 220 patients underwent 410 kidney-
allograft biopsies, and 265 did not undergo biopsy. The numbers of patients with biopsy-
matched urine samples (urine samples that were collected from 3 days before to 1 day after
biopsy and that passed QC) are shown for patients with acute cellular rejection (defined as
Banff grade IA or higher), for those without any rejection features in the biopsy sample, for
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those with acute antibody-mediated rejection, for those with borderline changes, and for
those with other biopsy findings. The number of patients listed under different diagnostic
categories exceeds the 220 patients who underwent biopsy because several patients had
multiple biopsies with different diagnoses. Among the 265 patients who did not undergo
biopsy, 202 met the criteria for stable graft function, of whom 201 had urine samples that
passed QC (from Suthanthiran et al. N Engl J Med 2013, with permission).
Lee et al. Page 18













Fig. 3. Levels of mRNA in urinary cells
Box-and-whisker plots show the log10-transformed ratios of mRNA copies per microgram
of total RNA to 18S ribosomal RNA (rRNA) copies (X10−6) per microgram of total RNA
for CD3ε, perforin, granzyme B, interferon-inducible protein 10 (IP-10), CXCR3, CD103,
transforming growth factor β1 (TGF-β1), and proteinase inhibitor 9 in 43 urine samples
matched to 43 biopsy specimens (from 34 patients) showing acute cellular rejection, 163
urine samples matched to 163 biopsy specimens (from 126 patients) showing no rejection,
and 1540 longitudinally collected urine samples from 201 patients with stable graft function
who did not undergo biopsy. The horizontal line within each box represents the median, the
bottom and top of each box represent the 25th and 75th percentile values, and the thin
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vertical bars extend to the 10th and 90th percentile values; the diamond indicates the mean,
and circles indicate outliers. The mRNA levels of CD3ε, perforin, granzyme B, and IP-10
differed significantly among the three groups (P<0.001 for all comparisons), but not the
levels of CXCR3 (P = 0.06), CD103 (P = 0.13), TGF-β1 (P = 0.11), and proteinase inhibitor
9 (P = 0.38). P values are based on the Kruskal–Wallis test, with the log10-transformed,
18S-normalized mRNA levels treated as the dependent variable. Pairwise group
comparisons by means of the Mann–Whitney test showed that the 18S-normalized mRNA
levels for CD3ε, perforin, granzyme B, and IP-10 in patients with acute cellular rejection
were significantly higher than the levels in those with specimens showing no rejection
(P<0.001 for each mRNA) and in those with stable graft function (P<0.001 for each mRNA)
(from Suthanthiran et al. N Engl J Med 2013, with permission).
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Fig. 4. Receiver-operating-characteristic curves and calibration curve for the diagnostic
signature
The fraction of true positive results (sensitivity) and false positive results (1-specificity) for
the diagnostic signature (calculated from 18S-normalized CD3ε mRNA, 18S-normalized
IP-10 mRNA and 18S rRNA, all logged) as biomarker of ACR are shown in Panels A, B,
and C, and the calibration plot based on bootstrap validation is shown in panel D. The area
under the curve (AUC) was 0.85 (95 percent confidence interval, 0.78–0.91) for ACR vs. No
Rejection Biopsy group (Panel A), 0.81 (95 percent confidence interval, 0.75–0.87) for ACR
vs. Stable (no biopsy) group (Panel B) and 0.56 (95 percent confidence interval, 0.51–0.61)
for No Rejection Biopsy group vs. Stable (no biopsy) group (Panel C). Adding 18S-
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normalized perforin to the best-fitting model provided no additional improvement, largely
because perforin was very highly correlated with CD3ε. Alternative combinations of mRNA
for perforin and IP-10 or perforin and CD3ε also predicted ACR accurately; the AUC for the
combination of 18S-normalized perforin mRNA, 18S-normalized IP-10 mRNA and 18S
rRNA was 0.84 (95% confidence Interval 0.78–0.90; P<0.0001), and this combination
discriminated ACR biopsies with a sensitivity of 77% and a specificity of 76%. The AUC
for the combination of 18S-normalized-CD3ε mRNA, 18S-normalized-perforin mRNA and
18S rRNA was 0.84 (95% confidence interval 0.76–0.91; P<0.0001), and this combination
discriminated ACR with a sensitivity of 77% and a specificity of 74%. Additional analyses
of the discriminating ability of single mRNA measures showed that the AUC for ACR vs.
No Rejection Biopsy group was 0.70 for 18S rRNA, 0.71 for granzyme B, 0.74 for perforin,
0.75 for CD3ε, and 0.75 for IP-10. A value of 0.5 is no better than chance (the null
hypothesis) and a value of 1.0 indicates a perfect discriminator. Bootstrap validation
identified the optimal model to include 18S-normalized CD3ε mRNA, 18S-normalized
IP-10 mRNA and 18S rRNA as predictors. Optimism-corrected estimates of the AUC,
Cox’s intercept and slope statistics were: 0.830, −0.06, and 0.92, respectively. The Loess-
smoothed estimates of the calibration curves of the optimism-adjusted and the unadjusted
calibration curves are overlaid on a diagonal reference line representing perfect model
calibration (Panel D). None of the single-marker models calibrated as well as the 3-gene
model. Based on these results, the 3-gene model of 18S-normalized CD3ε mRNA, 18S-
normalized IP-10 mRNA and 18S rRNA, all logged, is superior to any of the single-gene
models considered and the three-gene diagnostic signature can be expected to perform well
in an independent population of patients (from Suthanthiran et al. N Engl J Med 2013, with
permission).
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Fig. 5. Prospective longitudinal trajectory of diagnostic signature as a function of time since
kidney transplantation
Sequential urine specimens collected from study participants as per the CTOT-04 study
protocol on post-transplant days 3, 7, 15 and 30 and months 2, 3, 4, 5, 6, 9 and 12 were
analyzed. The average within-person trajectories and 95% confidence bands of the
diagnostic signature for the ACR group (n=195 QC-passed urine samples obtained prior to 3
days before the first ACR biopsy from 38 patients who had no abnormal biopsy prior to their
first ACR biopsy) (Panel A), No Rejection Biopsy group (n=960 QC-passed urine samples
from 132 patients for whom all biopsies were rejection free) (Panel B), Stable (no biopsy)
group (n=1491 QC-passed urine samples from 201 patients) (Panel C). In all panels, the
black lines of the LOESS curves indicate the trajectory, the colored bands the 95%
confidence interval, and the red lines the diagnostic threshold. On average, the diagnostic
signature in the No Rejection Biopsy group and in the Stable (no biopsy) group remained
well below the −1.213 threshold diagnostic for ACR throughout the first 400 days post-
transplant whereas a progressive increase in the signature was seen in the urine samples of
those who went on to develop ACR. By about 80 days post-transplant there was a clear
signal that the future ACR patients have elevated values (the lower bound of the 95%
confidence band for this group exceeds the upper bound of the 95% confidence bands for the
two other groups), and beyond about 160 days the average value for the future ACR patients
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is greater than or equal to the threshold diagnostic for ACR (Panel D). The y-axis values are
diagnostic-signature scores without intrinsic units of measurement; they were calculated
from the logistic-regression equation (−6.1487 + 0.8534 log10[CD3ε/18S] + 0.6376
log10[IP-10/18S] + 1.6464 log10[18S]). Absolute levels of CD3ε mRNA, IP-10 mRNA, and
18S rRNA in the cells from each urine sample were measured with the use of polymerase-
chain reaction assays, with the units of measurement being copies per microgram of total
RNA for each mRNA measure and 18S rRNA copies (×10-6) per microgram of total RNA.
The mRNA copy numbers were 18S-normalized by dividing the mRNA copy number by the
18S rRNA copy number in the same sample, and the ratio was log10-transformed (from
Suthanthiran et al. N Engl J Med 2013, with permission).
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Fig. 6. Retrospective trajectory of diagnostic signature as a function of time prior to biopsy
The average within-person retrospective trajectory of the diagnostic signature (i.e., the
trajectory as a function of the time before biopsy) in urine samples obtained at or before
biopsy that passed quality control are shown for the group of 38 patients with first biopsy
specimens showing acute cellular rejection (201 urine samples) (Panel A) and the group of
113 patients with specimens showing no rejection (833 urine samples) (Panel B). Only
specimens obtained during the first 400 days after transplantation were included. The
diagnostic signature remained relatively flat and well below the −1.213 threshold that was
diagnostic of acute cellular rejection during the 270 days before biopsy in the group of
patients with findings showing no rejection (Panel C). There was a significant difference in
the trajectories between the two groups, with a marked increase in the diagnostic signature
during the 20-day period before the first specimen showing acute cellular rejection
(P<0.001) (Panel D). The y-axis values are diagnostic-signature scores without intrinsic
units of measurement; they were calculated from the logistic-regression equation (−6.1487 +
0.8534 log10[CD3ε/18S] + 0.6376 log10[IP-10/18S] + 1.6464 log10[18S]). Absolute levels
of CD3ε mRNA, IP-10 mRNA, and 18S rRNA in the cells from each urine sample were
measured by polymerase-chain-reaction assay, with the units of measurement being copies
per microgram of total RNA for each mRNA measure and copies (×10-6) per microgram of
total RNA for 18S rRNA. The mRNA copy numbers were 18S-normalized by dividing the
mRNA copy number by the 18S rRNA copy number in the same sample, and the ratio was
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log10-transformed. In all the panels, the black lines indicate the trajectory, the colored bands
the 95% confidence interval, and the red lines the diagnostic threshold (from Suthanthiran et
al. N Engl J Med 2013, with permission).
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Fig. 7. Flow chart for the discovery and validation of urinary cell mRNA profiles
The 114 kidney allograft recipients (48 with biopsies showing fibrosis and 66 with normal
biopsy results) were rank ordered within group (Fibrosis group or Normal Biopsy group) by
the copy number of 18S rRNA and partitioned into triplets. Within each triplet, the first and
third patients were assigned to the Discovery set and the second patient was assigned to the
Validation set, resulting in the two sets being exactly matched on fibrosis status and very
closely matched on 18S rRNA copy number. Twice as many patients were assigned to the
Discovery set in order to enhance statistical power for the exploratory analyses, which
included a procedure to protect against the risk of a Type I error (from Anglicheau et al.
Transplantation 2012, with permission).
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Fig. 8. Predicted probability of fibrosis as a function of urinary cell mRNA copy number in the
Discovery set, for LOESS model and piece-wise linear logistic regression model, after controlling
for 18S rRNA copy number
Urine samples were collected from 32 kidney transplant recipients with graft dysfunction
and biopsy-confirmed fibrosis and 44 recipients with stable allograft function and normal
allograft biopsy, and levels of mRNA in urinary cells were measured with the use of pre-
amplification enhanced kinetic quantitative PCR assays. The figure shows the predicted
probability of fibrosis (Y-axis), controlling for 18S rRNA, as a function of individual log10-
transformed mRNA copy numbers for these genes (X-axis). Each plot shows the LOESS
model’s predicted probabilities (dotted line), their 95% confidence interval (shaded area)
and the logistic regression model’s predicted probabilities (solid line). According to the
logistic models, the levels of twelve of the twenty-two mRNAs (vimentin, HGF, α-SMA,
fibronectin 1, perforin, PAI1, TGF-β1, TIMP1, granzyme B, FSP1, CD103, and collagen
1A1) were significantly (P-values <0.05 with modified Bonferroni correction) associated
with the diagnosis of fibrosis. Adjusted P-value for each parametric model is shown. The
number of stable patients, number of fibrosis patients, and percentage of fibrosis patients
within categories of the mRNA measure appear in each plot (from Anglicheau et al.
Transplantation 2012, with permission).
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Fig. 9. Final model derived from the discovery set for the diagnosis of fibrosis
The predicted probability of fibrosis (y-axis) as a function of individual log10-transformed
messenger RNA (mRNA) copy numbers (x-axis) for vimentin (Panel A), NKCC2 (Panel B),
and E-cadherin (Panel C) after controlling for the copy numbers for the other two mRNAs
and 18S rRNA is shown. Each plot shows the locally weighted scatterplot smoothing
(LOESS) model’s predicted probabilities (dotted line), their 95% confidence interval (CI)
(shaded area), and the logistic regression model’s predicted probabilities (solid line). The
parameter estimates for the four-gene model including terms accounting for the
relationships, including nonlinear relationships, between the mRNAs and diagnosis are
provided in Panel D (from Anglicheau et al. Transplantation 2012, with permission).
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Fig. 10. Relationship of composite score to fibrosis in the Discovery set, ROC curve analysis of
the composite score in the Discovery set and the Validation set and the predicted and observed
number of transplant recipients with fibrosis for each sextile of the composite score within the
Discovery and Validation sets
To predict fibrosis in the Discovery set, a composite score was calculated based on a logistic
model, from vimentin mRNA, NKCC2 mRNA and E cadherin mRNA as well as the 18S
rRNA in urine samples obtained from the 32 subjects with biopsy-confirmed fibrosis and 44
subjects with stable graft function and normal allograft biopsy. The composite score
predicted fibrosis with high accuracy. Panel A shows the predicted probability of fibrosis
(Y-axis) as a logistic function of the composite score (X-axis). The blue band represents the
95% confidence interval of the model. Panel B shows the receiver-operating-characteristic
curve for the diagnosis of fibrosis using the composite score. The model had an area under
the curve of 0.95 (95%CI: 0.90 to 0.99, P<0.0001). At a cutpoint or 4.5, fibrosis was
diagnosed with a specificity of 84.1% (95%CI: 73.3 to 94.9%) and a sensitivity of 93.8%
(95%CI: 85.4 to 99.9%). The final prediction equation derived from the Discovery set was
used to calculate the predicted probability of fibrosis in the Validation set of 38 kidney
transplant recipients; 16 with biopsy-confirmed fibrosis and 22 with stable graft function
and normal allograft biopsy. Panel C shows the receiver-operating characteristic curve of the
composite score (applying the equation from Figure 9D to the urinary cell mRNA levels of
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vimentin, NKCC2 and E-cadherin and 18S rRNA level of those in the Validation set) for the
diagnosis of fibrosis. The area under the curve for the diagnosis of fibrosis in the Validation
set was 0.89 (95%CI: 0.78 to 0.99, P<0.0001). At the composite score cutpoint of 4.5
derived from the Discovery set, fibrosis was diagnosed in the Validation set with a
specificity of 77.3% (95%CI: 59.8 to 94.8%) and a sensitivity of 87.5% (95%CI: 71.3 to
99.9%). Panel D shows the predicted and observed number of transplant recipients with
fibrosis for each sextile of the composite score within the Discovery and Validation sets
(from Anglicheau et al. Transplantation 2012, with permission).
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Fig. 11. Mean level and 95%confidence intervals of the 4-gene composite score by Banff
diagnostic category
Mean level and 95%CI of the 4-gene composite score by fibrosis grade. Kidney allograft
biopsies were classified as normal, mild fibrosis (grade I, <25% of cortical area), moderate
(grade II, 26–50% of cortical area), or severe (grade III, >50% of cortical area). The mean
(and 95%CI) composite scores derived from urinary cell vimentin, NKCC2 and E-cadherin
mRNA levels and 18S rRNA level were significantly different across the four groups
(P<0.0001, one-way ANOVA). Pairwise comparisons revealed that the mean composite
score of normal biopsies was significantly different from those of mild fibrosis (P=0.0002,
Tukey’s honestly significant differences criterion), moderate fibrosis (P<0.0001) and severe
fibrosis (P<0.0001). Within the fibrosis group, however, the mean composite scores were
not significantly different (mild vs. moderate [P=0.64], mild vs. severe [P=0.65] and
moderate vs. severe [P=0.99]). Values under each biopsy diagnosis show the number of
kidney graft recipients from whom urine samples were collected for the measurement of
urinary cell mRNA (from Anglicheau et al. Transplantation 2012, with permission).
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Fig. 12. Levels of mRNA in urinary cells of Tolerant, Stable, and Healthy Controls
Total RNA was isolated from urinary cells and pre-amplification enhanced real time
quantitative PCR assays were used to measure levels of mRNAs in urinary cells. Transcript
levels were normalized using 18s rRNA and log transformed. Boxes depict IQR; whiskers
denote 1.5 × IQR; values beyond this range are considered outliers and shown as circles. P
values are shown for statistically significant differences (P<0.05) (From Newell et al Journal
of Clinical Inestigation 2010, with permission).
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Fig. 13. Schema of acute cellular rejection in the kidney allograft
The immune repertory contributing to acute cellular rejection involves multiple cell types,
cytokines and chemokines and their ligands. T cells are the prime effector cells and dendritic
cells are the primary antigen presenting cells. In this minimalist model, IP-10 and its
receptor CXCR3 expressed on T cells function to facilitate the trafficking of alloreactive T
cells to the kidney graft. Intraepithelial homing of the T cells is then effected by the physical
interaction between CD103 expressed on the T cells and E-cadherin expressed on the tubular
epithelial cells. The activated T cells employ perforin and granzyme to mediate parenchymal
cell damage, which is antagonized in part by the endogenous antagonist PI-9. Counter-
regulatory mechanisms such as FoxP3 expressing Tregs help dampen the anti-allograft
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response and the ultimate outcome of an episode of acute rejection is determined in part by
the balance between the graft destructive cells and graft protective cells. Although the cells
with different functional attributes appear to have different pedigrees, plasticity may exist
based on environmental cues. In this T cell centric formulation, the antigen-experienced T
cells provide help to B cells and facilitate antibody-mediated rejection. Acute rejection is a
precursor of chronic rejection manifested histologically by IF/TA. Acute rejection associated
tissue injury, de-differentiation and repair (? epithelial/endothelial-mesenchymal transition)
contribute to the pathogenesis of IF/TA and progressive loss of allograft function. The levels
of mRNA encoding vimentin, αSMA, E-cadherin and NKCC2 in urinary cells reflect these
cellular events quantitatively. The mRNAs, colored red in the schematic illustration, have all
been detected and quantified using urinary cell mRNA profiling and found to be associated
with human kidney allograft status.
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Table 1
Oligonucleotide Primers and TaqMan Probes used to Measure Levels of mRNA in the
CTOT-04 Study
The sequences and the locations of the oligonucleotide primers and probes that we designed and validated for
the measurement of mRNA levels and 18S ribosomal RNA (rRNA) in the urine are shown. The fluorogenic
TaqMan probes were labeled with 6-carboxy-fluorscein (FAM) at the 5’ end and with 6-carboxy-
tetramethylrodamine (TAMRA) or minor groove binder (MGB) at the 3’ end. FAM functioned as the reported







CD3-epsilon NM_000733 Sense: 5'-AAGAAATGGGTGGTATTACACAGACA-3' 131–156
Antisense: 5'-TGCCATAGTATTTCAGATCCAGGAT-3' 233–209
Probe: 5'-FAM-CCATCTCTGGAACCACAGTAATATTGACATGCC-TAMRA-3' 170–202
Perforin M28393 Sense: 5'-GGACCAGTACAGCTTCAGCACTG-3' 492–514
Antisense: 5'-GCCCTCTTGAAGTCAGGGTG-3' 587–568
Probe: 5'-FAM-TGCCGCTTCTACAGTTTCCATGTGGTACAC-TAMRA-3' 526–555
Granzyme B J04071 Sense: 5'-GCGAATCTGACTTACGCCATTATT-3' 534–557
Antisense: 5'-CAAGAGGGCCTCCAGAGTCC-3' 638–619
Probe: 5’-FAM-CCCACGCACAACTCAATGGTACTGTCG-TAMRA-3’ 559–585
IP-10 NM_001565.1 Sense: 5'-TGTCCACGTGTTGAGATCATTG-3' 235–256
Antisense: 5'-GGCCTTCGATTCTGGATTCA-3' 309–290
Probe: 5’-FAM TACAATGAAAAAGAAGGGTGAGAA-MGB-3’ 258–281
CXCR3 NM_001504 Sense: 5'-ACCCAGCAGCCAGAGCAC-3' 41–58
Antisense: 5'-CAACCTCGGCGTCATTTAGC-3' 117–98
Probe: 5'-FAM-CTTGGTGGTCACTCACCTCAAGGACCAT-TAMRA-3' 69–96
CD103 XM_008508 Sense: 5'-CGTGCTCAGCTCCCTTCTG-3' 211–229
Antisense: 5'-CCTGGTGTCCTCTTGGTTCTG-3' 297–277
Probe: 5’-FAM-ACCAAGACCCCAGCACCAACCATACCT-TAMRA-3’ 231–257




PI-9 NM_004155 Sense: 5'-'TCAACACCTGGGTCTCAAAAAA-3' 508–529
Antisense: 5'- CAGCCTGGTTTCTGCATCAA-3' 590–571
Probe: 5’-FAM-AGCTACCCGGCAACAACTCTTCAATTTTACCT-TAMRA −3’ 536–567
18S rRNA K03432 Sense: 5'-GCCCGAAGCGTTTACTTTGA-3' 929–948
Antisense: 5'-TCCATTATTCCTAGCTGCGGTATC-3' 1009–986
Probe: 5’-FAM-AAAGCAGGCCCGAGCCGCC-TAMRA-3’ 965–983
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Table 3
Oligonucleotide Primers and TaqMan Probes used to Measure Levels of mRNA for the
Noninvasive Diagnosis of IF/TA
The sequences and the locations of the oligonucleotide primers and probes that we designed and validated for
the measurement of mRNA levels and 18S ribosomal RNA (rRNA) in the urine are shown. The fluorogenic
TaqMan probes were labeled with 6-carboxy-fluorscein (FAM) at the 5’ end and with 6-carboxy-
tetramethylrodamine (TAMRA) or minor groove binder (MGB) at the 3’ end. FAM functioned as the reported






Vimentin NM_003380.2 Sense: 5’ TCAGAGAGAGGAAGCCGAAAAC 3’ 706–727
Antisense: 5’ CCAGAGACGCATTGTCAACATC 3’ 770–749
Probe: 5’ FAM CCCTGCAATCTTTCAGAC MGB 3’ 729–746
HGF BC063485 Sense: 5' CAAATGTCAGCCCTGGAGTTC 3' 526–546
Antisense: 5' CTGTAGGTCTTTACCCCGATAGCT 3' 604–581
Probe: 5’ FAM ATGATACCACACGAACACAGCTTTTTGCC TAMARA 3’ 548–576
α -SMA NM_001613 Sense: 5’ TGGGACGACATGGAAAAGATC 3’ 288–308
Antisense: 5’ CAGGGTGGGATGCTCTTCAG 3’ 365–346
Probe: 5’ FAM CCACTCTTTCTACAATGAGCTTCGTGTTGCC TAMRA 3’ 314–344
Fibronectin 1 XM_055254 Sense: 5' GAAAGTACACCTGTTGTCATTCAACA 3' 2582–2607
Antisense: 5' ACCTTCACGTCTGTCACTTCCA 3' 2688–2666
Probe: 5' FAM CCACTGGCACCCCACGCTCA TAMRA 3' 2613–2632
PAI1 NM_000602.1 Sense: 5’ AATCAGACGGCAGCACTGTCT 3’ 716–736
Antisense: 5’ GGGCGTGGTGAACTCAGTATAGT 3’ 792–770
Probe: 5’ FAM TGTGCCCATGATGGC MGB 3’ 738–752
Perforin M28393 Sense: 5' GGACCAGTACAGCTTCAGCACTG 3' 492–514
Antisense: 5' GCCCTCTTGAAGTCAGGGTG 3' 587–568
Probe: 5' FAM TGCCGCTTCTACAGTTTCCATGTGGTACAC TAMRA 3' 526–555
TGFI31 NM_000660 Sense: 5' GCGTGCTAATGGTGGAAACC 3' 1170–1189
Antisense: 5' CGGAGCTCTGATGTGTTGAAGA 3' 1263–1242
Probe: 5’ FAM ACAACGAAATCTATGACAAGTTCAAGCAGAGTACACA TAMRA 3’ 1191–1227
TIMP1 NM003254 Sense: 5’ GACGGCCTTCTGCAATTCC 3’ 288–306
Antisense: 5’ GTATAAGGTGGTCTGGTTGACTTCTG 3’ 366–341
Probe: 5’ FAM AGGGCCAAGTTCGTGG MGB 3’ 319–334
Granzyme B J04071 Sense: 5' GCGAATCTGACTTACGCCATTATT 3' 534–557
Antisense: 5' CAAGAGGGCCTCCAGAGTCC 3' 638–619
Probe: 5’ FAM CCCACGCACAACTCAATGGTACTGTCG TAMRA 3’ 559–585
FSP1 CR450345.1 Sense: 5’ AGGAGCTGCTGACCCGG 3’ 104–120
Antisense: 5’ GCTTCATCTGTCCTTTTCCCC 3’ 158–138
Probe: 5’ FAM CTGCCCAGCTTCT MGB 3’ 124–136
CD103 XM_008508 Sense: 5' CGTGCTCAGCTCCCTTCTG 3' 211–229
Antisense: 5' CCTGGTGTCCTCTTGGTTCTG 3' 297–277



















Probe: 5’ FAM ACCAAGACCCCAGCACCAACCATACCT TAMRA 3’ 231–257
Collagen 1A1 NM_000088.3 Sense: 5' CCAGAAGAACTGGTACATCAGCAA3' 4050–4073
Antisense: 5' CGCCATACTCGAACTGGAATC3' 4144–4124
Probe: 5’ FAM ACAAGAGGCATGTCTGG MGB 3’ 4085–4101
BMP7 NM_001719.1 Sense: 5' GCTTCGTCAACCTCGTGGAA 3' 526–545
Antisense: 5’ CAAACCGGAACTCTCGATGGT 3’ 597–577
Probe: 5’ FAM ATGACAAGGAATTCTTCCACCCACGCTAC TAMRA 3’ 547–575
CTLA4 BC074893 Sense: 5’ CGCCATACTACCTGGGCATAG 3’ 441–461
Antisense: 5 GATCCAGAGGAGGAAGTCAGAATC 3’ 529–506
Probe: 5’ FAM CAGATTTATGTAATTGATCCAGAACCGTGCCC TAMRA 3’ 473–504
CTGF NM_001901 Sense: 5’ TGTGTGACGAGCCCAAGGA 3’ 639–657
Antisense: 5’ TAGTTGGGTCTGGGCCAAAC 3’ 725–706
Probe: 5’ FAM CCTGCCCTCGCGGCTTACCG TAMRA 3’ 674–693
FGF2 NM_002006.3 Sense: 5’ CCGACGGCCGAGTTGAC 3’ 601–617
Antisense: 5’ TAACGGTTAGCACACACTCCTTTG 3’ 712–689
Probe: 5’ FAM ACCCTCACATCAAGCTACAACTTCAAGCAGAA TAMRA 3’ 637–668
CD25 NM_000417 Sense: 5’ GACTGCTCACGTTCATCATGGT 3’ 185–206
Antisense: 5’ AATGTGGCGTGTGGGATCTC 3’ 266–247
Probe: 5' FAM AGAGCTCTGTGACGATGACCCGCC TAMRA 3' 222–245
FoxP3 NM_014009 Sense: 5’ GAGAAGCTGAGTGCCATGCA 3’ 939–958
Antisense: 5 GGAGCCCTTGTCGGATGAT 3’ 1025–1007
Probe: 5’ FAM TGCCATTTTCCCAGCCAGGTGG TAMRA 3’ 962–983
USAG1 NM_015464 Sense: 5' TGGAGGCAGGCATTTCAGTAA 3' 364–366
Antisense: 5' TTCCCGGCAACCCACTT 3' 412–396
Probe: 5' FAM CCCGAGTGTTCCGATCCAGTCCAGT TAMRA 3' 392–368
NKCC2 BC040138.2 Sense: 5’ TCACGAGCAACTCGCAAAGA 3’ 588–607
Antisense: 5’ TCCCATCACCGTTAGCAACTC 3’ 658–638
Probe: 5’ FAM TGTGGCAGTCACCCCAAGTTCAGC TAMRA 3’ 609–632
ITGB6 NM_000888.3 Sense: 5’ GGATTGAACTGCTTTGCCTGTT 3’ 21–42
Antisense: 5’ GGCACAGCCACCTTGTACGT 3’ 69–88
Probe: 5’ FAM TTTCTATTTCTAGGAAGGAATG MGB 3’ 44–65
E-cadherin XM_007840 Sense: 5' TGAGTGTCCCCCGGTATCTTC 3' 2469–2489
Antisense: 5' CAGCCGCTTTCAGATTTTCAT 3' 2549–2529
Probe: 5' FAM CCTGCCAATCCCGATGAAATTGGAAAT TAMRA 3' 2495–2521
18S rRNA K03432 Sense: 5' GCCCGAAGCGTTTACTTTGA 3' 929–948
Antisense: 5' TCCATTATTCCTAGCTGCGGTATC 3' 1009–986
Probe: 5’ FAM AAAGCAGGCCCGAGCCGCC TAMRA 3’ 965–983
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